Compare XPOF & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XPOF | ACOG |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.6M | 193.6M |
| IPO Year | 2021 | 2024 |
| Metric | XPOF | ACOG |
|---|---|---|
| Price | $3.82 | $8.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $8.13 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 554.7K | 153.2K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.24 | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,092,000.00 | $10,220,275.00 |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | $6.63 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.77 | $4.50 |
| 52 Week High | $9.25 | $10.14 |
| Indicator | XPOF | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 26.21 | 44.47 |
| Support Level | $3.83 | $7.50 |
| Resistance Level | $6.15 | $9.04 |
| Average True Range (ATR) | 0.30 | 0.51 |
| MACD | -0.09 | -0.12 |
| Stochastic Oscillator | 11.17 | 13.91 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.